Gestational diabetes & diabetes in pregnancy
Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial
Primary result · Glucose AUC during OGTTResult — go to the resultEstimated treatment difference −173 mmol/L × min 95% CI −250 to −97Authors' conclusion
Treatment with liraglutide for 52 weeks improved glucose tolerance, FPG, HbA1c and bodyweight in women with overweight/obesity and pGDM. Progression to prediabetes while on drug was markedly reduced, but after a 1-week drug wash-out, the effect was lost.
Study context
- Population
- Women with overweight/obesity and previous GDM; mean age 38 ± 5 years, fasting plasma glucose (FPG) 5.5 ± 0.4 mmol/L, HbA1c 33 ± 4 mmol/mol, BMI 31.1 ± 4.3 kg/m²
- Participants
- 104 women
- Comparison
- Once-daily SC liraglutide 1.8 mg vs placebo for 52 weeks
- Liraglutiden = 49
- Placebon = 55reference
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
Glucose AUC during oral glucose tolerance test (OGTT) · 52 weeks
Estimated treatment difference
−173 mmol/L × min
95% CI −250 to −97
P < 0.0001
Liraglutidevs Placebo
estimated treatment difference −173 mmol/L × min (95% CI −250 to −97); P < 0.0001
As reported in the abstract
Further findings
| Outcome | ETD (mmol/L × min) (CI) | P value | |
|---|---|---|---|
| Glucose AUC during OGTT after drug wash-out · after 1-week wash-out | 58 (−30 to 146) | P = 0.536 | |
| −1000100200Difference, mmol/L × min (linear scale) |
| Outcome | ETD (mmol/L) (CI) | P value | |
|---|---|---|---|
| FPG | −0.2 (−0.4 to −0.1) | P = 0.018 | |
| −0.6−0.4−0.200.2Difference, mmol/L (linear scale) |
| Outcome | ETD (mmol/mol) (CI) | P value | |
|---|---|---|---|
| HbA1c | −2.2 (−3.5 to −0.8) | P = 0.018 | |
| −4−202Difference, mmol/mol (linear scale) |
| Outcome | ETD (kg) (CI) | P value | |
|---|---|---|---|
| Bodyweight | −3.9 (−6.2 to −1.6) | P = 0.012 | |
| −10−505Difference, kg (linear scale) |
| Outcome | Liraglutide | Placebo | aOR (CI) | P value | |
|---|---|---|---|---|---|
| Prediabetes | 10% | 50% | 0.10 (0.03–0.32) | P = 0.002 | |
| 0.050.21520Adjusted odds ratio (log scale) |
- Prediabetes: reduced from 64% at baseline
Incretin effect
- No change in the incretin effect was observed
Original publication
Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial. Diabetes Obes Metab. Published 17 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →